Aytu BioScience (AYTU) AI Stock Analysis

• Market Cap: $23.00M
• Dividend Yield: N/A
• Average Volume (3M): 313.11K
• Price to Earnings (P/E): ―
• Beta (1Y): 1.82
• Revenue Growth: -18.05%
• EPS Growth: 33.87%
• Country: US
• Employees: 102
• Sector: Healthcare
• Sector Strength: 45
• Industry: Drug Manufacturers - Specialty & Generic
• EPS (TTM): -2.93
• Shares Outstanding: 9,911,913
• 10 Day Avg. Volume: 289,454
• 30 Day Avg. Volume: 313,109
• PEG Ratio: 0.04
• Price to Book (P/B): 0.72
• Price to Sales (P/S): 0.21
• P/FCF Ratio: -6.32
• Enterprise Value/Market Cap: 0.30
• Enterprise Value/Revenue: 0.10
• Enterprise Value/Gross Profit: 0.15
• Enterprise Value/Ebitda: 1.32
• 1Y Price Target: $9.17
• Price Target Upside: 300.44% Upside
• Rating Consensus: Strong Buy
• Number of Analyst Covering: 3

• Rating: 50 Neutral
• Price Target: $2.50 ▲(9.17% Upside)

Aytu BioScience's overall stock score reflects significant financial challenges and a concerning valuation, partially offset by optimism around the upcoming ExuA launch and positive technical indicators. The company's strategic initiatives and potential market expansion offer some promise, but financial and competitive pressures remain substantial.

Positive Factors

ExuA Launch

The launch of ExuA, a novel treatment for MDD, positions Aytu to capture market share in a $22 billion market, potentially driving significant revenue growth and strengthening its competitive position.

Positive Adjusted EBITDA

Sustained positive adjusted EBITDA indicates operational efficiency and financial health, providing a stable foundation for future investments and growth initiatives.

Pediatric Portfolio Growth

Growth in the pediatric portfolio reflects successful execution of Aytu's growth strategy, enhancing revenue diversification and reducing reliance on a single market segment.

Negative Factors

Decline in Gross Margin

The decline in gross margin suggests rising costs and potential pricing pressures, which could impact profitability if not addressed through cost management or pricing strategies.

ADHD Portfolio Stability Concerns

Flat revenue in the ADHD portfolio and potential generic competition pose risks to market share and revenue stability, necessitating strategic responses to maintain competitiveness.

Impairment Expense Impact

The impairment expense reflects strategic shifts and potential misallocation of resources, impacting financial performance and highlighting the need for careful portfolio management.

Aytu BioScience Business Overview & Revenue Model

Company Description

Aytu Biopharma, Inc., a specialty pharmaceutical company, focuses on developing and commercializing novel therapeutics and consumer healthcare products the United States and internationally. The company offers Adzenys XR-ODT for the treatment of attention deficit hyperactivity disorder (ADHD) in patients from 6 years and older; Cotempla XR-ODT for the treatment of ADHD in patients from 6 to 17 years old; and Adzenys ER, an oral suspension for the treatment of ADHD in patients from 6 years and older. It also provides Karbinal ER, a carbinoxamine oral suspension for the treatment of seasonal and perennial allergies; Poly-Vi-Flor and Tri-Vi-Flor prescription supplements for infants and children for the treatment of fluoride deficiency; Tuzistra XR, a prescription antitussive consisting of codeine polistirex and chlorpheniramine polistirex in an oral suspension; and ZolpiMist, an oral spray for the treatment of insomnia. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu Biopharma, Inc. in March 2021. Aytu Biopharma, Inc. was incorporated in 2015 and is headquartered in Englewood, Colorado.

How the Company Makes Money

Aytu BioScience generates revenue through the sale of its pharmaceutical products and diagnostic tests. The company has a diversified revenue model that includes direct sales of its proprietary products, as well as partnerships with other pharmaceutical companies for co-promotion and distribution. Key revenue streams are derived from product sales in the urology and pediatric markets, where Aytu has established a presence. Additionally, the company may benefit from licensing agreements, collaborations, and research grants that contribute to its financial performance. Strategic partnerships with healthcare providers and institutions also play a crucial role in expanding its market reach and enhancing sales.

Aytu BioScience Financial Statement Overview

Summary

Aytu BioScience faces significant financial challenges, with declining revenues and persistent losses impacting profitability. While the company maintains a manageable debt level, its negative return on equity and cash flow issues highlight the need for strategic improvements to enhance financial stability and growth prospects.

Income Statement

Aytu BioScience's income statement reveals challenges with profitability and revenue growth. The company has experienced a decline in revenue over the past year, with a negative revenue growth rate of -4.10%. Gross profit margin remains relatively strong at 69.04%, indicating efficient production, but the net profit margin is negative at -20.43%, reflecting ongoing losses. EBIT and EBITDA margins are also negative, highlighting operational inefficiencies.

Balance Sheet

The balance sheet shows a moderate debt-to-equity ratio of 0.10, suggesting manageable leverage. However, the return on equity is significantly negative at -71.51%, indicating poor returns for shareholders. The equity ratio stands at 15.27%, showing a reasonable proportion of equity financing relative to total assets.

Cash Flow

Cash flow analysis indicates a concerning decline in free cash flow growth at -62.28%. The operating cash flow to net income ratio is negative, reflecting cash flow challenges. However, the free cash flow to net income ratio is positive at 1.12, suggesting that free cash flow covers net losses, albeit with limited margin.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	66.38M	66.38M	81.00M	107.40M	96.67M	65.63M
Gross Profit	45.83M	45.83M	49.37M	66.63M	46.44M	29.20M
EBITDA	5.13M	-7.83M	-1.01M	-3.27M	-98.74M	-29.04M
Net Income	-13.56M	-13.56M	-15.84M	-17.05M	-108.78M	-58.29M
Balance Sheet
Total Assets	124.43M	124.18M	118.09M	136.46M	137.62M	265.67M
Cash, Cash Equivalents and Short-Term Investments	30.95M	30.95M	20.01M	22.98M	19.36M	49.65M
Total Debt	22.94M	1.86M	16.42M	18.45M	18.19M	28.35M
Total Liabilities	105.46M	105.21M	90.38M	97.11M	93.31M	128.10M
Stockholders Equity	18.97M	18.97M	27.72M	39.36M	44.31M	137.57M
Cash Flow
Free Cash Flow	-5.17M	-2.17M	-1.39M	-5.13M	-28.82M	-28.30M
Operating Cash Flow	-1.94M	-1.94M	-1.39M	-5.13M	-28.82M	-25.96M
Investing Cash Flow	-2.56M	-2.56M	-329.00K	-117.00K	-3.25M	-2.78M
Financing Cash Flow	15.44M	15.44M	-1.26M	8.87M	1.53M	30.31M

Aytu BioScience Technical Analysis

• Technical Analysis Sentiment: Positive
• Last Price: 2.29
• 50DMA: Positive
• 100DMA: Positive
• 200DMA: Positive
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For AYTU, the sentiment is Positive. The current price of 2.29 is above the 20-day moving average (MA) of 2.17, above the 50-day MA of 2.24, and above the 200-day MA of 1.81, indicating a bullish trend. The MACD of 0.03 indicates Negative momentum. The RSI at 52.26 is Neutral, neither overbought nor oversold. The STOCH value of 46.36 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Positive sentiment for AYTU.

Aytu BioScience Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
COSM	54 Neutral	$33.81M	―	-52.69%	―	―	―
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
AYTU	50 Neutral	$23.00M	―	-60.76%	―	-18.05%	33.87%
TXMD	47 Neutral	$12.10M	―	-1.98%	―	156.93%	92.75%
FLGC	44 Neutral	$13.54M	―	-230.73%	―	-24.10%	38.17%

Aytu BioScience Corporate Events

Aytu BioScience Expands Lending Agreement for EXXUA Launch

On June 20, 2025, Aytu BioPharma, Inc. expanded and extended its lending agreement with Eclipse Business Capital LLC to provide added working capital flexibility in anticipation of the commercial launch of EXXUA™ in late 2025. This agreement includes extending the term loan maturity to June 2029, increasing the principal balance to $13.0 million, and expanding the revolving credit facility by $1.5 million. EXXUA, a novel antidepressant, is expected to enter the over $22 billion U.S. prescription MDD market, addressing significant unmet needs due to its favorable side effect profile demonstrated in clinical trials.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Closes $16.6M Stock Offering for EXXUA

On June 9, 2025, Aytu BioPharma announced the closing of an upsized at-the-market public offering of common stock, raising gross proceeds of $16.6 million. The funds are intended to support the commercialization of EXXUA™, a novel FDA-approved treatment for major depressive disorder, which is expected to launch in the fourth quarter of 2025. This strategic move positions Aytu to enter the $22 billion U.S. prescription MDD market, with EXXUA expected to be a significant growth driver due to its unique mechanism and favorable side effect profile.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Signs Exclusive Agreement for EXXUA

On June 5, 2025, Aytu BioPharma entered an Exclusive Commercialization Agreement with Fabre-Kramer Holdings to commercialize EXXUA™ (gepirone) extended-release tablets in the United States. EXXUA, an FDA-approved treatment for major depressive disorder (MDD), is expected to launch in the fourth quarter of 2025. The agreement involves a series of financial commitments, including upfront and milestone payments, royalties, and a supply price based on net sales. EXXUA is anticipated to be a significant growth catalyst for Aytu, addressing unmet needs in the $22 billion US prescription MDD market. The product is distinguished by its novel mechanism and lack of sexual dysfunction side effects, positioning it as a transformative option for over 21 million Americans affected by MDD.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioPharma Announces $12.9M Public Offering

On June 5, 2025, Aytu BioPharma announced an underwriting agreement with Lake Street Capital Markets for a public offering of common stock and prefunded warrants, aiming to raise approximately $12.9 million. The proceeds will be used for general corporate purposes and to commercialize EXXUA™ (gepirone) extended-release tablets. The offering, expected to close around June 9, 2025, is part of Aytu’s strategy to strengthen its market position in novel therapeutics for major depressive disorder.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.

Aytu BioScience Holds 2025 Annual Meeting

On May 21, 2025, Aytu BioScience held its 2025 Annual Meeting, where approximately 70% of the company’s common stockholders participated. During the meeting, all incumbent directors were reelected, an amendment to increase shares under the 2023 Equity Incentive Plan was approved, Grant Thornton LLP was ratified as the independent accounting firm, and executive compensation was endorsed through a non-binding advisory vote.

The most recent analyst rating on (AYTU) stock is a Buy with a $8.00 price target. To see the full list of analyst forecasts on Aytu BioScience stock, see the AYTU Stock Forecast page.